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A B S T R A C T
Background
Inhaled anticholinergics as single agent bronchodilators (or in combination with beta2-agonists) are one of the several medications
available for the treatment of acute asthma in children.
Objectives
To determine the effectiveness of only inhaled anticholinergic drugs (i.e. administered alone), compared to a control in children over
the age of two years with acute asthma.
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), and the Cochrane Airways Group Register of trials were searched by the
Cochrane Airways Group. The latest search was performed in April 2011.
Selection criteria
We included only randomised controlled trials (RCTs) in which inhaled anticholinergics were given as single therapy and compared
with placebo or any other drug or drug combinations for children over the age of two years with acute asthma.
Data collection and analysis
Two authors independently selected trials, extracted data and assessed trial quality.
Main results
Six studies met the inclusion criteria but were limited by small sample sizes, various treatment regimes used and outcomes assessed. The
studies were overall of unclear quality. Data could only be pooled for the outcomes of treatment failure and hospitalisation. Other data
could not be combined due to divergent outcome measurements. Meta-analysis revealed that children who received anticholinergics
alone were significantly more likely to have treatment failure compared to those who received beta2-agonists from four trials on 171
children (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). Also, treatment failure on anticholinergics alone was more likely than when
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anticholinergics were combined with beta2-agonists from four trials on 173 children (OR 2.65; 95% CI 1.2 to 5.88). Data on clinical
scores/symptoms that were measured on different scales were conflicting. Individual trials reported that lung function was superior
in the combination group when compared with anticholinergic agents used alone. The use of anticholinergics was not found to be
associated with significant side effects.
Authors’ conclusions
In children over the age of two years with acute asthma exacerbations, inhaled anticholinergics as single agent bronchodilators were less
efficacious than beta2-agonists. Inhaled anticholinergics were also less efficacious than inhaled anticholinergics combined with beta2-
agonists. Inhaled anticholinergic drugs alone are not appropriate for use as a single agent in children with acute asthma exacerbations.
P L A I N L A N G U A G E S U M M A R Y
Anticholinergic therapy for acute asthma in children
Asthma is a condition that affects the airways (tubes carrying air in and out of the lungs). During an asthma exacerbation (attack),
the airways narrow and drugs can be taken to dilate, or widen, the airways. Common bronchodilators (medicines used to widen the
airways) are short-acting beta2- agonists (e.g. salbutamol) or anticholinergics (e.g. ipratropium bromide). In this review, we examined
if the use of anticholinergic inhalers during an asthma attack in children aged over two years is effective compared to either placebo or
another bronchodilator. We also looked at combinations of anticholinergic plus a beta2-agonist compared to an anticholinergic on its
own.
We found six small trials of unclear quality answering these two questions. We found data from four trials on 171 children comparing
anticholinergics with beta2-agonists. Children on anticholinergics alone were significantly more likely to experience treatment failure
than those on beta2-agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). We also found data from four trials on 173 children
comparing children on anticholinergics alone with children on anticholinergics plus beta2-agonists. In this case, treatment failure was
more likely in children taking anticholinergics only than if they were combined with beta2-agonists (OR 2.65; 95% CI 1.2 to 5.88).
We were only able to combine data for treatment failure and hospitalisation.
In summary, we found that inhaled anticholinergics used on their own are less effective than inhaled beta2-agonists used alone or in
combination with anticholinergics. Inhaled anticholinergics seem safe, with no significant side effects apparent.
B A C K G R O U N D
Inhaled anticholinergics as single agent bronchodilators (or in
combination with beta2-agonists) are one of the several medica-
tions available for the treatment of acute asthma in children. Ipra-
tropium bromide, an inhaled anticholinergic agent, has been used
extensively in emergency departments as adjunctive therapy with
beta2-agonists for the emergency treatment of acute asthma exac-
erbations. The objective of this review was to determine the effec-
tiveness of only inhaled anticholinergic drugs (i.e. administered
alone), compared to a control or combination treatment in chil-
dren over the age of two years with acute asthma.
Description of the condition
Asthma is an inflammatory disorder of the airways in which many
cells and cellular elements play a role. In susceptible individuals,
this inflammation causes recurrent episodes of wheezing, breath-
lessness, chest tightness and cough.These episodes are usually asso-
ciated with widespread but variable airflow obstruction that is of-
ten reversible either spontaneously or with treatment. The inflam-
mation also causes an associated increase in the existing bronchial
hyperresponsiveness to a variety of stimuli (NHLBI 2007). Air-
flow obstruction (excessive airway narrowing) in asthma is the re-
sult of contraction of the airway smooth muscle and swelling of
the airway wall due to smooth muscle hypertrophy and hyperpla-
sia, inflammatory cell infiltration, oedema, goblet cell andmucous
gland hyperplasia, mucous hypersecretion, protein deposition in-
cluding collagen and epithelial desquamation. Potential triggers
for the inflammatory process in asthma include allergy, viral res-
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piratory infections, irritants such as tobacco smoke, air pollutants
and occupational dusts, gases and chemicals, certain drugs, and
non-specific stimuli such as cold air exposure and exercise (NAC
2006).
Description of the intervention
Inhaled anticholinergics are bronchodilators. Ipratropium bro-
mide is the most studied anticholinergic bronchodilator, and now
most widely used of anticholinergic agents. Ipratropium bromide
has been used extensively in emergency departments as adjunc-
tive therapy with beta2-agonists for the emergency treatment of
acute asthma exacerbations. Multiple doses of anticholinergics in
combination with beta2-adrenergic agents have shown to be ben-
eficial in adults (Undem 2001) and of some merit in school-aged
children with severe asthma exacerbation (Plotnick 2008). Cur-
rent guidelines recommend the use of a combination of inhaled
beta2-agonists and anticholinergics, particularly for patients with
acute severe or life-threatening asthma in the emergency setting.
Anticholinergics tend not to be used as first-line drugs for asthma
exacerbation (Gross 1988).
Inhaled anticholinergics are the drugs of choice in bronchospasm
provoked by psychogenic stimuli and beta2-blockers (Gross 1988;
Beakes 1997). Ipratropium bromide also appears to have some
benefit in nocturnal asthma (Beakes 1997). However, the prin-
cipal clinical use of ipratropium bromide is in the treatment of
adult patients with chronic obstructive pulmonary disease (Brown
2001).
How the intervention might work
Airway calibre is controlled in health and disease by many in-
fluences. The parasympathetic nervous system is one among the
many mechanisms, which regulates the airway calibre by vary-
ing the bronchomotor tone. Muscarinic receptors are widely dis-
tributed in the airways and the release of acetylcholine at these
sites results in both smooth muscle contraction and release of se-
cretions from submucosal glands. An opportunity for therapeutic
intervention exists at the level of these muscarinic receptors. An-
ticholinergics such as atropine and its analogues are competitive
inhibitors of acetylcholine and may result in bronchodilatation by
reducing the tone of smooth muscles (Gross 1988).
Anticholinergic agents act at muscarinic receptors, competitively
inhibiting the effects of acetylcholine. Acetylcholine acts by caus-
ing smooth muscle constriction, which provides bronchomotor
tone. By antagonising the effects of acetylcholine, cholinergic
bronchomotor tone is inhibited and the vagal reflexes that medi-
ate bronchoconstriction are blocked (McDonald 2010). Choliner-
gic-induced bronchoconstriction appears to involve primarily the
large airways, whereas beta2-agonist medications relax both large
and small airway constriction equally (Rodrigo 2002).
Ipratropiumbromide (8-isopropyl-noratropine-methobromide) is
a synthetic quaternary ammonium congener of atropine. Iprat-
ropium bromide differs from atropine and other naturally occur-
ring anticholinergic alkaloids in one major aspect - it is insoluble
in lipids (although freely soluble in water) and crosses biological
barriers with difficulty. One could thus describe ipratropium bro-
mide as a topical form of atropine and hence virtually free of sys-
temic side effects. Neither atropine nor ipratropium bromide is
selective for the subtypes of muscarinic receptors. It was the first
anticholinergic agent to be approved for use as a bronchodilator
in adults and children (for acute asthma in children), with a wide
therapeutic margin of safety and has no important side effects
(Gross 1988; Brown 2001). Ipratropium bromide is a less potent
bronchodilator than beta2-adrenergic agents. The onset of action
of ipratropium is slower than short-acting beta2-adrenergic agents
(30 to 90 minutes versus 5 to 15 minutes).
Why it is important to do this review
The role of anticholinergic drugs for wheezing in children un-
der the age of two years has been reviewed (Everard 2005). The
authors concluded that there is not enough support for the un-
critical use of anticholinergic therapy for wheezing under the age
of two years. The review by Plotnick et al focused specifically on
combined treatment with anticholinergics and beta2-agonists in
asthmatic children over the age of two years and concluded that
anticholinergics plus beta2-agonists have a beneficial effect over
beta2-agonists alone in improving lung function significantly and
the addition of multiple doses of anticholinergics to beta2-agonists
reduced the risk of hospital admissions in children with predom-
inantly severe exacerbations (Plotnick 2008). Plotnick et al also
found that there was no conclusive evidence for using multiple
doses of anticholinergics in childrenwithmild ormoderate asthma
exacerbations. There is good evidence for the safety and efficacy
of frequent doses of ipratropium bromide (every 20 to 30 min-
utes) used in addition to beta2-agonists for the first two hours of a
severe asthma attack in children over two years (BTS 2009). The
addition of ipratropium bromide to beta2-agonists for severe acute
asthma may lead to some improvement in clinical symptoms and
reduce the need for more intensive treatment in children less than
two years. It does not significantly reduce the length of hospital
stay either in combination with beta2-agonists or in comparison
with placebo (Everard 2005; BTS 2009).
When investigating the therapeutic effect of an agent that may be
used in combination with another agent, it is important to estab-
lish separately the effectiveness of both the agents over placebo. It
is also essential to compare the beneficial effect of the combined
agents over placebo as well as the individual agents. In this way it
is possible to establish: a) if the single agents have a therapeutic
effect; and b) if there is an additive or synergistic effect from com-
bining the agents.
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This review focuses on the effectiveness of anticholinergic drugs
(without beta2-agonists) in children aged over two years with
acute asthma. By comparing the effect of anticholinergics as single
agents with that of other single agents and with combined ther-
apy (anticholinergics with beta2-agonists) as reviewed previously
(Plotnick 2008), we aim to establish the role of anticholinergics
as a monotherapy in the treatment of children over two years of
age with acute asthma.
O B J E C T I V E S
To determine the effectiveness of inhaled anticholinergic drugs
(used alone) compared to a control or combination treatment in
children over the age of two years with acute asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) in which only
inhaled anticholinergics were given comparedwith placebo, or any
other drug, or drug combinations for children over the age of two
years with acute asthma.
Types of participants
We included trials of children aged two to eighteen years with
acute asthma in all settings (emergency room, observation unit,
in-patient, out-patient, general practice and home). Asthma must
have been physician diagnosed or must have satisfied the criteria
established internationally (such as BTS 2009 guidelines).
We excluded studies involving children under the age of two
years since difficulties arise in establishing the diagnosis of asthma
unequivocally. Also they have been reviewed previously (Everard
2005).
Types of interventions
Inhaled anticholinergic drugs delivered by anymeans; nebulised or
by metered dose inhalers with or without spacer devices, and with
or without facemask. We included all doses and dosing regimens.
We included the following comparisons.
1. Anticholinergics versus placebo.
2. Anticholinergics versus beta2-agonists.
3. Anticholinergics versus anticholinergics plus beta2-agonists.
4. Anticholinergics versus any other drugs or drug
combinations.
Types of outcome measures
Outcome measures in the studies are summarised in Table 1.
Primary outcomes
1. Treatment failure
2. Admission to hospital
Secondary outcomes
1. Changes in symptoms or symptom scores
2. Requirement for additional medication
3. Changes in pulmonary function tests (peak expiratory flow
(PEF) and forced expiratory volume in one second (FEV1))
4. Effects on oxygenation
5. Duration of hospital stay
6. Adverse effects
7. Withdrawals
Search methods for identification of studies
The methods used to identify the studies are summarised below.
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register of trials (CAGR), which is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE,CINAHL, AMED, and PsycINFO, and handsearching
of respiratory journals and meeting abstracts (please see Appendix
1 for further details). We searched all records in the CAGR coded
as ’asthma’ using the following terms:
(“cholinergic antagonists” or “anticholinergic” or “anti-cholin-
ergic” or “cholinergic” or “muscarinic” or “antimuscarinic” or
“ipratropium” or “tiotropium” or “atropine” or “atrovent” or
“oxitropium” or “Sch1000” or “duovent”, all as (textword) or
(MeSH )) AND (“asthma” or “wheez” or “respiratory sounds”
or “bronchial spasm”, “bronchospas” or “bronch” or “spasm” or
“bronchoconstrict” or “bronchoconstriction” or “bronch” or “con-
strict”, all as (textword) or (MeSH )) AND (“adolescent” or
“child” or “paediat” or “pediat” or “infan” or “toddler” or “bab” or
“young” or “preschool” or “pre school” or “pre-school” or “new-
born” or “new born” or “new-born” or “neo-nat” or “neonat”, all
as (textword) or (MeSH )).
We also conducted an additional search of CENTRAL (see
Appendix 2). We searched all databases from their inception to
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April 2011 and we imposed no restriction on the language of pub-
lication.
Searching other resources
We checked reference lists of all primary studies and review articles
for additional references.
Data collection and analysis
From the title, abstract, or descriptors, two review authors (LT
and AC) independently reviewed literature searches to identify
potentially relevant trials for full review. We conducted searches
of bibliographies and texts to identify additional studies.
Selection of studies
From the full text, using specific criteria, two reviewers (LT and
AC) independently selected trials for inclusion. We resolved dis-
agreement by consensus.
Data extraction and management
LT and AC extracted data for the trials for the outcomes above.
We combined all trials using Review Manager 5 (RevMan 2011).
Assessment of risk of bias in included studies
Two review authors (LT and AC) performedmethodological qual-
ity assessment, using the ’risk of bias’ tool described in theCochrane
Handbook of Systematic Reviews of Interventions (Higgins 2011),
focusing on:
• random sequence generation;
• allocation concealment; and
• blinding
We graded each domain as either ’high’, ’low’ or ’unclear’ risk of
bias.
Measures of treatment effect
We obtained all outcomes directly from the publications of the
included studies.
Continuous Outcomes
For continuous outcomes measured on the same metrics, we cal-
culated individual and pooled statistics as weighted mean differ-
ences (WMDs) with 95% confidence intervals (CIs). For contin-
uous outcomes measured on different metrics, we combined data
with a standardised mean difference (SMD).
Dichotomous Outcomes
For dichotomous variables, we calculated individual and pooled
statistics as odds ratios (ORs) with 95% CIs.
Unit of analysis issues
None relevant.
Dealing with missing data
The review authors did not contact any study authors as it was not
felt necessary and the studies were also not recent.
Assessment of heterogeneity
We initially pooled all data with a fixed-effectmodel.Wemeasured
heterogeneity using the I2 statistic (a measure of the degree of
inconsistency between pooled studies). We used a random-effects
model to determine the impact of the variation in the results on
the overall effect estimate.
Assessment of reporting biases
We planned to investigate publication bias by visually inspecting
a funnel plot if ten or more trials had been included in a single
meta-analysis.
Data synthesis
We grouped outcomes relating to studies according to:
1. anticholinergic agents versus beta2- agonists; and
2. anticholinergic agents versus combination of
anticholinergic agents plus beta2- agonists.
We pooled outcomes that were reported in the studies when pos-
sible, in accordance with primary and secondary outcomes.
Subgroup analysis and investigation of heterogeneity
We examined the influence of trial characteristics on the observed
treatment effect. Assuming sufficient numbers of trials and the
availability of necessary data, we described clinical heterogeneity
with respect to treatment setting and asthma severity.
• Age: two to five years versus five to eighteen years.
• Co-interventions: with corticosteroids versus none.
• Different delivery methods of anticholinergics: metered
dose inhaler (MDI) versus nebuliser.
• Duration of anticholinergics administration: less than seven
days versus more than seven days duration.
• Asthma severity: mild and moderate versus severe asthma.
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Sensitivity analysis
Sensitivity analyses provide an approach for testing how robust the
results of a review are relative to key decisions and assumptions
that have been made in the process of conducting the review. We
planned to investigate the overall study quality of the pooled result
using the Cochrane approach.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search are summarised below.
Results of the search
Of the 349 abstracts that we identified, we retrieved 81 papers
for full assessment by the reviewers (LT and AC). After exclud-
ing articles that focused on adult patients or articles that did not
use inhaled anticholinergics as single agents for comparison (see
Characteristics of excluded studies for reasons for exclusion), seven
studies (one paper was an abstract from a conference proceeding
of a paper (Van Bever 1994)) from six trials met the inclusion
criteria for the review (Cook 1985; Guill 1987; Watson 1988;
Van Bever 1994; Calvo 1998; Ni 2003). See ’Characteristics of
included studies’ for full details on each study.
Included studies
Study design
All studies were randomised and double-blind except Ni 2003. All
studies were of a parallel group design.
Participants
The included studies involved children between the ages of two
and eighteen years who were treated for acute asthma. These stud-
ies recruited patients mainly from the emergency room (Cook
1985; Guill 1987). Van Bever 1994 and Watson 1988 did not
refer to the study setting. Cook 1985 and Watson 1988 included
patients with moderately severe asthma. Guill 1987 included pa-
tients of any severity of acute asthma andused episodes ofwheezing
for randomisation rather than individual patients. Calvo 1998 re-
cruited participants who did not require hospitalisation andwhose
peak expiratory flow (PEF) was less than 80%. Symptom scores
indicated that participants were suffering from moderately severe
acute asthma (Calvo 1998).
Interventions
Route/Delivery
Three studies used nebulisers to deliver therapy (Cook 1985; Guill
1987; Watson 1988). These studies utilised a Hudson nebuliser
with face mask but different models and techniques for driving
therapy. Cook 1985 used an oxygen (8 litres/min) driven nebuliser
unit and Watson 1988 used an air (7 litres/min) driven nebuliser.
Guill 1987 did not describe the driving gas for the nebuliser. Ni
2003 used an oxygen driven nebuliser but no further details were
available (translated paper). Calvo 1998 and Van Bever 1994 used
a holding chamber and MDI.
Type of drug/dosage
Differing drugs, doses and dosing regimens were used in the six
studies.
Calvo 1998: Three groups (ipratropium versus salbutamol versus
ipratropium + salbutamol). Salbutamol 100 mcg (two inhalations;
total 200 mcg per dose) four times in the first hour and three times
in the subsequent hour at regular intervals, versus ipratropium
bromide 20 mcg (two inhalations; total 40 mcg per dose) at the
same time-points versus combination salbutamol and ipratropium
(equivalent doses to the parallel component therapies) at the same
time-points. Also, Calvo 1998 allowed for the addition of inhaled
salbutamol or oral steroids where participants were deemed poor
responders to therapy.
Cook 1985: Three groups (ipratropium versus fenoterol versus
ipratropium + fenoterol). 0.025% (250 mcg/mL) solution of ipra-
tropium bromide versus 0.5% (5000 mcg/mL) fenoterol solution
versus combination 0.025% (250 mcg/mL) ipratropium bromide
and 0.5% (5000 mcg/mL) fenoterol. The doses of both fenoterol
and ipratropium bromide solution were adjusted according to the
age of the children.
Guill 1987: Three groups (atropine versus metaproterenol versus
atropine + metaproterenol). Atropine sulfate (0.05 to 0.1 mg/kg
i.e. 500 to 1000 mcg/kg) versus 5% (50,000 mcg/mL) metapro-
terenol versus combination (5%metaproterenol and atropine sul-
fate). The dose of metaproterenol was adjusted to age and the dose
of atropine sulfate was adjusted to weight.
Ni 2003:Three groups (ipratropiumversus salbutamol versus ipra-
tropium + salbutamol). 0.5% (5000 mcg/mL) salbutamol (0.25
to 1 mL i.e. 1250 to 5000 mcg) versus 0.025% (250 mcg/mL)
ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg) versus
combination (salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg)
and ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg)).
The dose of both salbutamol and ipratropium bromide solution
were adjusted according to the age of the children.
Van Bever 1994: Two groups (oxitropium versus fenoterol). Ox-
itropium bromide 200 mcg versus fenoterol 200 mcg. Subse-
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quently all patient received 400 mcg fenoterol in an open label
study.
Watson 1988: Three groups (ipratropium versus fenoterol versus
ipratropium + fenoterol). Ipratropium bromide 250 mcg versus
fenoterol 625 mcg versus combination (ipratropium bromide 250
mcg plus fenoterol 625 mcg).
Measurements of outcomes
Outcomes measured differed between the studies. For an overview
of the outcomes measured in the studies, please see Table 1.
Definition of treatment failure varied between the studies. Guill
1987 considered three criteria for treatment failure (return visit
to the emergency department within 12 to 24 hours; intravenous
(IV) treatment; or admission to hospital). Watson 1988 consid-
ered admission to hospital as treatment failure and Cook 1985
set IV therapy as indication of treatment failure. Calvo 1998 did
not report any pre-defined treatment failure criteria, although this
study reported that treatment was stopped if the TAL score was
less than 2, if there was a poor response to the therapy and/or PEF
was less than 15% at first measurement or if there was intolerance
to the treatment (TAL score is a clinical scoring system based on
several markers such as respiratory rate, wheezing and cyanosis;
the scale runs from 0 to 12, where 12 indicates a very severe ill-
ness; Tal 1983). Poor response to therapy was defined in terms of
change in PEF + 4% or less.
Four of the included studies used symptom scores: Calvo 1998
measured symptoms on the TAL scale; Watson 1988 and Guill
1987 used pulmonary index which used a scale of 0 to 12; and
Cook 1985 used a clinical score on an in-house four-point scale.
Cook 1985 and Guill 1987 measured repeat nebulisations as one
of their outcome measures. Watson 1988 did not measure addi-
tionalmedication. Calvo 1998measured need for additional bron-
chodilation and steroid therapy.
Guill 1987 used improvement in PEF as one of their objective
measures, while Watson 1988 elaborately measured spirometric
functions (forced expiratory volume in 1 second (FEV1), forced
expiratory flow at the 25 to the 75% point of forced vital ca-
pacity (FEF25−75) and forced vital capacity (FVC)), at various
time intervals to monitor the change. In addition to the improve-
ment in the oxygen saturations, Watson 1988 also determined
whether bronchodilation was still possible after study medication
had been given, by administering open label salbutamol and mea-
suring spirometry.
Excluded studies
We excluded studies that focused on adult patients or that did not
use inhaled anticholinergics as single agents for comparison (see
Characteristics of excluded studies for reasons for exclusion).
Risk of bias in included studies
Our judgement on the risk of bias for included studies is sum-
marised in Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
We judged two studies to be at low risk of bias for random se-
quence generation (Guill 1987; Van Bever 1994). The randomi-
sation method was less well described in four studies and we there-
fore judged them to be at unclear risk of bias (Cook 1985;Watson
1988; Calvo 1998; Ni 2003).
Blinding
We judged four studies to be at low risk of bias for blinding (Cook
1985; Guill 1987; Van Bever 1994; Calvo 1998), while we were
unclear about the risk of bias in Watson 1988 and we judged Ni
2003 to be at high risk of bias.
Calvo 1998: Blinding and randomisation were referred to, but
were not described. Participants were excluded from study entry
if they required hospitalisation. No participants failed treatment
and all were accounted for. The addition of salbutamol and/or oral
steroids may have influenced the response to therapy across the
three groups.
Cook 1985:This study is described as a double-blind trial although
the method of double-blinding is not explicit. Three patients (one
from each group) required IV therapy and did not complete the
trial. Children of various age groups received different volumes
of the medicines in their respective groups, however, there is no
explanation of how this was done with the blinding intact.
Guill 1987: This study is described as a double-blind trial. Ran-
domisation was done for each episode of wheezing, rather than
for individual patients. Although the method of double-blinding
is explicit, it is difficult to explain how blinding was preserved
when subjects entered into the trial more than once and yet did
not receive the same treatment more than once. Ten episodes of
wheezing were classified as treatment failure, six of these were in
the group which received atropine sulfate only.
Ni 2003: This study is an unblinded trial. No patients withdrew or
dropped out. This paper was published in Chinese and translated.
Van Bever 1994: This study is described as a double-blind trial.
Medications were administered from blinded metered dose in-
halers. Withdrawals were not reported.
Watson 1988: This study is described as a double-blind trial al-
though the method of randomisation is not mentioned. No pa-
tients withdrew from the study because of the need for an ad-
ditional bronchodilator. Two children were admitted to hospital
at the end of the study because of failure to achieve a clinically
significant improvement. These patients were in the group which
received ipratropium bromide only.
Incomplete outcome data
Guill 1987 reported ten episodes of wheezing that were classified
as treatment failure (two in the group which received metapro-
terenol only, six in the group which received atropine sulfate only
and two in the groupwhich received combination treatment).One
study (Cook 1985) reported that three patients (one from each
group) required IV therapy and did not complete the trial and
hence we excluded the results of these patients from the analysis.
Withdrawals were not reported in Van Bever 1994’s study. No de-
tailed description was available for outcome measures in one study
which was published in Chinese and translated; but no patients
withdrew or dropped out (Ni 2003).
Selective reporting
Outcomes measured differed between the studies. Outcome mea-
sures in each individual study were reported.
One study (Ni 2003) reported outcome measures as “no symp-
toms” or “improved symptoms” (shortness of breath, wheeze and
hypoxia); no detailed description was available for outcome mea-
sures. Ni 2003 reported complete improvement in symptoms in
40 children and partial improvement in symptoms in 22 children
in the group treated with salbutamol in combination with iprat-
ropium bromide. However, only 55 children were allocated to this
group. This paper was published in Chinese and translated.
Other potential sources of bias
One study (Watson 1988) was supported by a grant from a phar-
maceutical company. Two studies (Guill 1987; Van Bever 1994)
received pharmaceutical company support for the medications.
Effects of interventions
Only data for anticholinergics versus beta2-agonists and anti-
cholinergics versus anticholinergics plus beta2-agonists were avail-
able. We entered relevant data into forest plots but were only able
to pool data for the outcomes of treatment failure and hospital-
isation. We could not pool other data due to divergent outcome
measurements, and different types of anticholinergic agents and
bronchodilators used in the studies. Results are presented accord-
ing to comparison and then by outcome, with the primary out-
come listed first.
Anticholinergic agents versus beta2-agonists
We were able to include all six studies (Cook 1985; Guill 1987;
Watson 1988; Van Bever 1994; Calvo 1998; Ni 2003) in this in-
tervention. However insufficient data (translated paper) was avail-
able from Ni 2003 and hence we did not include data from this
paper below.
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Primary outcome: treatment failure (analysis 1.1)
There is variability in the definition of ’treatment failure’, although
all required additional treatment. One study reported admission
data discreetly from treatment failure data (Watson 1988). The
other four studies reported data on treatment failure according to
their own pre-defined criteria (see Table 1). In one study (Calvo
1998), we considered treatment failure as those children who were
poor responders to bronchodilator therapy (PEF + 4% or less).
In another study (Cook 1985), we considered treatment failure as
those children who required intravenous therapy as well as those
who required repeat nebulizations of medications. In the study
of Guill 1987 and colleagues, treatment failure was considered as
those children who required repeat nebulizations of medications,
those who either worsened after nebulized treatment and required
alternative therapy (injectable epinephrine) or improved initially
after one or two nebulized treatments but deteriorated within one
hour and required hospitalisation. We could pool data from three
studies that used similar medications (ipratropium versus beta2-
agonist) (Cook 1985; Watson 1988; Calvo 1998). Pooled analy-
sis revealed a (just) significant difference between the two groups
with those who received ipratropium bromide more likely to have
treatment failure compared to those on beta2-agonist (OR 2.36;
95% CI 1.02 to 5.47; Analysis 1.1). The addition of Guill 1987’s
study (to the forest plot) that used atropine sulphate compared to
metaproterenol (9/13 versus 8/15, respectively) further strength-
ened the efficacy of beta2-agonists compared to anticholinergic
agents (OR 2.27; 95% CI 1.08 to 4.75) as depicted in Figure 2.
Figure 2. Forest plot of comparison: 1 Anticholinergic agents versus short-acting beta2-agonists, outcome:
1.1 Treatment failure.
Primary outcome: hospital admissions (analysis 1.2)
Three studies (Guill 1987; Watson 1988; Calvo 1998) reported
on this outcome but only two studies had children who required
hospitalisation (Guill 1987; Watson 1988). No admissions oc-
curred in the Calvo 1998 study. Pooled data from the two studies
(Calvo 1998; Watson 1988) that used similar medications (iprat-
ropium versus beta2-agonist) showed no significant difference be-
tween groups (OR 5.34; 95% CI 0.24 to 121.0). The addition of
Guill 1987’s study (to the forest plot) that used atropine sulphate
versus metaproterenol, revealed a significant difference between
the two groups, with those who received anticholinergic agents
more likely to result in a hospital admission compared to those on
beta2-agonists (OR 5.50; 95% CI 1.11 to 27.16; Analysis 1.2).
Secondary outcome: symptom scores
Guill 1987 and Watson 1988 reported pulmonary index scores
(composite scores of several outcome measures). Guill 1987 did
not report a significant difference between treatment groups at first
nebulisation. Watson 1988 reported that clinical scores improved
significantly in all treatment groups at all times (no P values were
reported).
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Calvo 1998 reported data on TAL score from eight measurements
over two hours.We only extracted data for the first 30minutes due
to concerns arising over the addition of a known bronchodilator
if there was a lack of improvement after 30 minutes. For results
taken up to 30 minutes for the three treatment groups, please see
Table 2. Significant differenceswere observed at 15 and 30minutes
for salbutamol versus ipratropium bromide (at 30 minutes: 3.3
(standard deviation (SD) 1.1) versus 4.2 (SD 0.9); P < 0.01).
Cook 1985 measured symptoms on an in-house symptom score
(see Table 1). No significant difference was reported between the
treatment groups across the two hours of treatment on clinical
rating.
Secondary outcome: requirement for additional medication
Calvo1998,Cook 1985 andGuill 1987measured the requirement
for additional treatment in different ways (see Table 1).
Calvo 1998 reported no significant difference in the requirement
for additional study medication between children on ipratropium
and those on salbutamol (5.3 (SD 1.1) versus 4.7 (SD 1.2); P >
0.05) respectively. Furthermore, there was no significant differ-
ence in the requirement for corticosteroids at 60 minutes between
children on ipratropium and those on salbutamol (0.3 (SD 0.4)
versus 0.2 (SD 0.4) respectively; P > 0.05). There was a signifi-
cant difference in terms of need for additional bronchodilators in
the ipratropium group compared with salbutamol (1.7 (SD 2.1)
versus 1.0 (SD 1.8); P < 0.05).
Cook 1985 reported the number of repeat nebulisations required.
No statistically significant differences were observed between treat-
ment groups.
Guill 1987 reported the number of treatments required.More par-
ticipants in the metaproterenol group (7/15) could be discharged
after fewer treatments than those in the atropine group (4/13).
No P value was reported for the metaproterenol group versus the
atropine group.
Secondary outcome: lung function
Data are presented by outcome (PEF and FEV1) and then by study.
We have extracted and presented data for outcome assessment at
30 and 120minutes where possible.We consider these time-points
to be the most clinically relevant in an asthma attack. P values
are presented from the published papers; some of these considered
data at all time-points.
PEF (percentage predicted)
Calvo 1998 reported no significant difference between salbutamol
(80.5 (SD 7)) and ipratropium (78.1 (SD 7.3)); P > 0.05 at 30
minutes (Analysis 1.3). We did not extract subsequent data due to
the potential for confounding by the introduction of concomitant
therapy in all groups.
Guill 1987 reported lung function at 20 to 30 minutes after treat-
ments were administered. We extracted data for lung function
taken after the first administration which corresponds approxi-
mately to 30 minute data. We did not observe any significant dif-
ferences between the groups at 30 (Analysis 1.3) minutes. We did
not include data extracted for subsequent lung function measure-
ment in the review as they represented assessment 20 to 30 min-
utes after a second treatment, and 40 to 60 minutes after the first
treatment.
FEV1
Watson 1988 reported non-significant differences when data were
analysed as absolute change in FEV1 and percentage change from
baseline. When Watson 1988 and colleagues analysed data as
change in percentage predicted, fenoterol was significantly better
than ipratropium alone (P = 0.02, at each time-point).
Absolute scores at 30 minutes were: ipratropium group 1.51 (SD
0.84) and fenoterol group 1.86 (SD 0.85) (Analysis 1.5).
Absolute scores at 120 minutes were: ipratropium group 1.48 (SD
0.8) and fenoterol group 1.89 (SD 0.89) (Analysis 1.7).
Van Bever 1994 reported lung function at 20 minutes after treat-
ments were administered. A significant improvement in FEV1 in
both groups (i.e. children on oxitropium bromide and those on
fenoterol) compared to baseline (82.9 SD (9.6); P 0.003). A sig-
nificant improvement in FEV1 was observed after administration
of 200 mcg oxitropium bromide or fenoterol and subsequent ad-
ministration of 400 mcg of fenoterol (87.2 (SD 11.0); P 0.03).
FEF25−75
One study (Watson 1988) reported results for FEF25−75 for the
comparison of ipratropium with fenoterol. There was a signifi-
cant difference between fenoterol and ipratropium in FEF25−75
whether considered as absolute change or as change in percentage
predicted (P < 0.05, no time-point specified).
Absolute scores at 30minutes were: ipratropium group 0.92 (SEM
0.15) and fenoterol group 1.40 (SEM 0.22).
Absolute scores at 120 minutes were: ipratropium group 0.94
(SEM 0.13) and fenoterol group 1.56 (SEM 0.25).
Secondary outcome: pulse oximetry
Watson 1988 reported that there was no significant difference be-
tween the two groups for pulse oximetry. However, there was a sig-
nificant improvement in oxygen saturation in the fenoterol group
at 30 minutes which continued throughout the study (no P value
reported). The improvement in oxygen saturation for ipratropium
alone was not statistically significant at 30 minutes, but was so at
60 minutes and thereafter (no P values reported).
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Secondary outcome: withdrawals
No withdrawals occurred in three studies (Watson 1988; Calvo
1998; Ni 2003). Three children dropped out from one study
(Cook 1985; one from each group). Guill 1987 reported the num-
ber of treatment failures. Because the primary outcome was the
number of additional treatments required before clinical improve-
ment was observed, participants only contributed data for subse-
quent clinical assessment if they had not improved subsequent to
the previous treatment; withdrawals were not therefore measured.
Van Bever 1994 did not report on withdrawals.
Secondary outcome: side effects
All studies reported no significant differences in side effects be-
tween the participants.
Anticholinergic agents versus combination of
anticholinergic agents + beta2-agonists
Primary outcome: treatment failure (analysis 2.1)
Four studies reported data on treatment failure according to their
own pre-defined criteria (see Table 1). In one study (Calvo 1998),
we considered treatment failure as those children who were poor
responders to bronchodilator therapy (PEF + 4% or less). In an-
other study (Cook 1985), we considered treatment failure as those
children who required intravenous therapy as well as those who
required repeat nebulizations of medications. In one study (Guill
1987), we considered treatment failure as those children who re-
quired repeat nebulizations of medications, those who either wors-
ened after nebulized treatment and required alternative therapy
(injectable epinephrine) or improved initially after one or two neb-
ulized treatments but deteriorated within one hour and required
hospitalization.We were able to pool data from three studies that
used similar medications (ipratropium versus beta2-agonist plus
ipratropium) (Cook 1985; Watson 1988; Calvo 1998). A signifi-
cant difference between anticholinergic and combination therapy
was observed (OR 3.67; 95% CI 1.41 to 9.50; Analysis 2.1) i.e.
those who received ipratropium alone were more likely to have
treatment failure compared to those on combination therapy.
Guill 1987 reported that 2 out of 16 participants failed treatment
in the combination (atropine and metaproterenol) group (P <
0.02) versus atropine sulfate alone. Combining these studies (anti-
cholinergics alone versus anticholinergic agents + beta2-agonists),
those who received anticholinergics alone were significantly more
likely to experience treatment failure compared to those who re-
ceived anticholinergic + beta2-agonists, Figure 3 (OR 2.65; 95%
CI 1.20 to 5.88).
Figure 3. Forest plot of comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting
beta2-agonists, outcome: 2.1 Treatment failure.
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Primary outcome: admission to hospital (analysis 2.2)
Three studies (Guill 1987;Watson 1988; Calvo 1998) reported on
this outcome but only two studies had children who required hos-
pitalisation (Guill 1987; Watson 1988). Pooled data from the two
studies that used similar medications (ipratropium versus beta2-
agonist plus ipratropium) showed no significant difference be-
tween groups (OR 5.69; 95% CI 0.25 to 128.5; Analysis 2.2).
The addition to the forest plot of Guill 1987’s study that used at-
ropine sulfate versus atropine sulfate and metaproterenol, revealed
a significant difference between the two groups with those who
received anticholinergic agents more likely to result in a hospital
admission compared to those on combination therapy (OR 5.90;
95% CI 1.20 to 29.05).
Secondary outcome: symptom scores
Guill 1987 and Watson 1988 reported pulmonary index scores.
Guill 1987 did not report a significant difference between treat-
ment groups at first nebulisation.Watson 1988 reported that clini-
cal scores improved significantly in all treatment groups at all times
(no P values were reported). Calvo 1998 reported data on TAL
score from eight measurements over two hours. We extracted data
only for the first 30 minutes due to concerns arising over the addi-
tion of a known bronchodilator if there was a lack of improvement
after 30 minutes. For results taken up to 30 minutes for the three
treatment groups, please see Table 2. Significant differences were
observed at 15 and 30 minutes for combination therapy versus
ipratropium (at 30 minutes 2.8 (SD 1.0) versus 4.2 (SD 0.9); P <
0.01). Cook 1985 measured symptoms on an in-house symptom
score (see Table 1). No difference was reported between the treat-
ment groups across the two hours of treatment on clinical rating.
Secondary outcome: requirement for additional medication
Calvo 1998, Cook 1985 and Guill 1987 measured the require-
ment for additional treatment in differentways (seeTable 1).Calvo
1998 reported a significant difference between combination ther-
apy and ipratropium in terms of study medication requirement
(3.7 (SD 1.1) versus 5.3 (SD 1.1) respectively; P < 0.01) and bron-
chodilator requirement (0.5 (SD 1.3) versus 1.7 (SD 2.1) respec-
tively; P < 0.01). There was a non-significant difference between
combination and ipratropium in terms of corticosteroid require-
ment (0.1 (SD 0.3) versus 0.3 (SD 0.4) respectively; P >0.05).
Cook 1985 reported the number of repeat nebulisations required.
No statistically significant differences were observed between treat-
ment groups. Guill 1987 reported the number of treatments re-
quired. More participants in the metaproterenol and combination
groups could be discharged after fewer treatments than those in
the atropine group (atropine group 4/13; combination group 5/
16). No P values were reported for the combination group versus
atropine group.
Secondary outcome: lung function
Data are presented by outcome (PEF and FEV1) and then by study.
We have extracted and presented data for outcome assessment at
30 and 120minutes where possible.We consider these time-points
to be the most clinically relevant in an asthma attack. P values
are presented from the published papers; some of these considered
data at all time-points.
PEF (percentage predicted)
Two studies (Guill 1987; Calvo 1998) reported PEF percentage
predicted. Calvo 1998 reported a significant difference between
the combination (85.1 (SD 6.7)) and ipratropium groups (78.1
(SD 7.3)); P < 0.01 at 30 minutes (Analysis 2.4). We did not ex-
tract subsequent data due to the potential for confounding by the
introduction of concomitant therapy in all groups. Guill 1987 re-
ported lung function at 20 to 30 minutes after treatments were ad-
ministered.We extracted data for lung function taken after the first
administration which corresponds approximately to 30 minute
data. No significant differences were observed between the groups.
We did not include data extracted for subsequent lung function
measurement in the review as they represented assessment 20 to
30 minutes after a second treatment, and 40 to 60 minutes after
the first treatment.
FEV1
Watson 1988 reported a significant difference between combina-
tion and ipratropiumalone in terms of absolute change, (P =0.005,
all time-points), change in percentage predicted (P = 0.0002, all
time-points; Analysis 2.6) and percentage change from baseline
(P = 0.002, all time-points). All data were presented graphically.
Absolute scores at 30 minutes were: combination group 1.94 (SD
0.93) and ipratropium group 1.51 (SD 0.84) (Analysis 2.6). Ab-
solute scores at 120 minutes were: combination group 2.11 (SD
1.05) and ipratropium group 1.48 (SD 0.8) (Analysis 2.7).
FEF25−75
One study (Watson 1988) reported this. A significant difference in
FEF25−75 was reported between the combination and ipratropium
group (P < 0.005, no time-point specified). Absolute scores at 30
minutes were: combination group 1.57 (SEM: 0.25) and iprat-
ropium group: 0.92 (SEM 0.15). Absolute scores at 120 minutes
were: combination group 1.82 (SEM: 0.3) and ipratropium group:
0.94 (SEM 0.13).
Secondary outcome: pulse oximetry
Watson 1988 reported that there were no significant differences
between the three groups. However, there was a significant im-
provement in oxygen saturation in the combination and fenoterol
groups at 30 minutes which continued throughout the study (no
P values reported).
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Secondary outcome: withdrawals
No withdrawals occurred in three studies (Watson 1988; Calvo
1998; Ni 2003). Three children dropped out from one study
(Cook 1985; one from each group). Guill 1987 reported the num-
ber of treatment failures. Because the primary outcome was the
number of additional treatments required before clinical improve-
ment was observed, participants only contributed data for subse-
quent clinical assessment if they had not improved subsequent to
the previous treatment; withdrawals were not therefore measured.
Van Bever 1994 also did not report on withdrawals.
Secondary outcome: side effects
All studies reported no significant differences in side effects be-
tween the participants.
D I S C U S S I O N
In this review, we evaluated the trials that studied the efficacy of
ipratropium bromide given alone or in combination with beta2-
agonists (compared to a control of beta2 -agonists) for acute asthma
in children aged over two years. Despite an extensive and thorough
literature search in which we found hundreds of papers examining
anticholinergic drugs, only seven studies (one paperwas an abstract
from a conference proceedings of a paper (Van Bever 1994)) from
six trials met the inclusion criteria for the review.
Summary of main results
We found that inhaled anticholinergic agents as single agent bron-
chodilators were less efficacious (i.e. led to more treatment failure)
than beta2-agonists in children over the age of two years with acute
asthma exacerbations. Anticholinergics were also less efficacious
(i.e. led tomore treatment failure) than anticholinergics combined
with beta2-agonists. In this review, data on clinical scores/symp-
toms that were measured on different scales were variable but all
generally showed that ipratropium bromide used alone was less
efficacious compared to beta2-agonists or combined with beta2-
agonists. Also, individual trials reported that lung function was
superior in the combination group when compared to anticholin-
ergic agents.
In our review, there was no significant increase in the occurrence
of tachycardia, tremor, mydriasis or dryness of oral mucous mem-
branes observed among participants treated with anticholinergic
agents. Ipratropium bromide has no or very little systemic toxic-
ity. Another significant advantage to ipratropium bromide in the
critically ill asthma patient is the lack of increase in heart rate,
which does occur with beta2-agonist use (Cugell 1986). The only
remarkable reported side effect in the literature is the inhibition
of salivary secretions at high doses. When nebulised, ipratropium
is very unlikely to affect urinary flow or intraocular tension, and
possible effects on the eye (i.e. glaucoma) can be prevented by us-
ing a mouthpiece during nebulisation. Although data is not avail-
able in children, the speed of onset of effect is reported in adults
with airway disease to be 3 to 30 minutes with up to 50% of the
response occurring in three minutes and 80% in 30 minutes, with
a peak bronchodilator effect observed within one to two hours,
and duration of action of up to approximately six hours (Gross
1988).
Overall completeness and applicability of
evidence
Our thorough systematic search for published and unpublished
trials resulted in identification of important trials. We could only
extract data from six trials. Despite the small number of studies,
we conclude from the studies that inhaled anticholinergic drugs
as single agent bronchodilators were less efficacious than beta2-
agonists and anticholinergics combined with beta2-agonists.
Quality of the evidence
This systematic review was limited by the quality of existing data.
In addition, there was clinical heterogeneity amongst the trials
and we could not pool some data due to divergent outcome mea-
surements and different types of anticholinergic agents and bron-
chodilators used in the studies. The number (i.e. six trials) and size
of studies pooled were small. There were limited data on hospital
admissions.
Potential biases in the review process
The studies were generally small with potential risk of bias as
shown in Figure 1.
Agreements and disagreements with other
studies or reviews
Inhaled anticholinergics in combination with beta2-agonists is
now the standard recommended treatment for children with acute
moderate to severe asthma exacerbations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In children over the age of two years with acute asthma exacerba-
tions, inhaled anticholinergic drugs as single agent bronchodila-
tors were less efficacious than beta2-agonists. Inhaled anticholin-
ergics on their own were also less efficacious than anticholinergics
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combined with beta2-agonists. Thus in children over the age of
two years with acute asthma exacerbations, inhaled anticholiner-
gics alone are not appropriate as a single agent. None of the major
asthma guidelines currently recommend inhaled anticholinergics
as a single agent and our review supports this. The use of anti-
cholinergics was not found to be associated with significant side
effects such as tachycardia, tremor, mydriasis or dryness of oral
mucous membranes.
Implications for research
Inhaled anticholinergics combined with beta2-agonists is now the
standard recommended treatment in guidelines for children with
acute moderate to severe asthma exacerbations. Thus, in light of
our conclusion above, we do not recommend any further trials
comparing inhaled anticholinergics as a single agent in children
with acute asthma exacerbations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Calvo 1998
Methods Randomised, double-blind parallel group trial. Method of randomisation not reported
Outpatient Setting
Participants N = 120 (Group 1: 40; Group 2: 40; Group 3: 40). 73 M/47 F. Mean age 7.3 years (age
range: 5 to 14 years). No withdrawals occurred and all participants were accounted for
• Inclusion criteria: age between 5 and 14 years; acute asthma attack; aerochamber
well used; able to use peak flow meter; PEF < 80% predicted; TAL score > 0 on 5-point
scale.
• Exclusion criteria: cardiac failure; lung disease; need for hospitalisation; first acute
episode of acute bronchial obstruction; hypersensitivity to trial medications; treatment
< 8 hours prior to study entry
Interventions All treatments were administered by aerochamber
• Group 1: salbutamol 100 mcg per inhalation
• Group 2: ipratropium bromide 20 mcg per inhalation
• Group 3: salbutamol 100 mcg per inhalation and ipratropium bromide 20 mcg
per inhalation
2 inhalations 4 times in first hour, 2 inhalations 3 times in second hour
Outcomes PEF; TAL score; need for additional treatment (salbutamol and oral steroids)
Notes Trial protocol allowed for addition of salbutamol (100 mcg per inhalation, 2 inhalations
after each control) to trial medicines if participants showed no response (clinical or PEF)
at 30 minutes or corticosteroid therapy at 60 minutes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
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Cook 1985
Methods Randomised double-blind parallel group trial. Method of randomisation not reported
Emergency Department setting
No intention to treat population
Participants N = 48 (Group 1: 16; Group 2: 16; Group 3: 16). 26 M/22 F. Mean age 6.6 years (age
range 18 months to 12 years). 3 withdrawals due to requirement of IV therapy (1 from
each group)
• Inclusion criteria: moderately severe acute asthma based on clinical presentation
• Exclusion criteria: patients deemed to require IV therapy
Interventions All treatments were administered via a Hudson nebuliser driven by oxygen (flow rate 8
L/min)
• Group 1: ipratoprium bromide (0.025%) 1 mL i.e. 250 mcg (1 to 4 years); 1.5
mL i.e. 375 mcg (5 to 8 years); 2 mL i.e. 500 mcg (9 to 12 years)
• Group 2: fenoterol (0.5%) 0.125 mL i.e. 625 mcg (1 to 4 years); 0.25 mL i.e.
1250 mcg (5 to 8 years); 0.5 mL i.e. 2500 mcg (9 to 12 years)
• Group 3: ipratropium bromide + fenoterol (same dosage as above)
Duration 2 hours. Repeat nebulisations at 2-hourly intervals until stable enough to return
to inhaled or oral medication
Outcomes Repeat nebulisation; pulse rate; respiratory rate; clinical rating of wheeze; air entry;
respiratory distress; overall index of response to treatment
Notes Plotnick and Ducharme contacted trialists and established that allocation concealment
was adequate
Different volumes of trial medication were given according to age of the participants in
each treatment group. The trial was described as ’double-blind’ and it was not reported
how the blinding of the trialists to the treatment was maintained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk All doses administered blind
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Guill 1987
Methods Randomised double-blind parallel group trial. Method of randomisation: computer-
generated random numbers table
Emergency department or outpatient setting
Participants N = 35 with 44 episodes of acute asthma (Group 1: 15; Group 2: 13; Group 3: 16)
26 M/18 F; age range: 13 months to 13 years
Interventions All treatments were administered via a Hudson 1700 updraft nebuliser and paediatric
face mask attached with standard oxygen tubing to a Pulmo-Aid compressor
• Group 1: metaproterenol 5% (50,000 mcg/mL), 0.2 mL (10,000 mcg) in < 12
years; 0.3 mL (15,000 mcg) ≥ 12 years in 2 mL normal saline
• Group 2: atropine sulfate 0.05 to 0.1 mg/kg, max 2.0 mg i.e. 500 to 1000 mcg/kg
in 2 mL normal saline
• Group 3: metaproterenol + atropine sulfate (same dosage as above)
Three doses of nebulised medicines were administered 20 to 30 minutes apart
Outcomes • Severity of bronchospasm as assessed by a pulmonary index score (0 to 12) at
entry and 20 minutes after each inhalation
• PEF measure at entry and at 20 minutes after each inhalation (in patients old
enough to perform manoeuvre)
• Number of treatments and treatment failure
Notes Computer generated random numbers were used for each episode rather than for indi-
vidual patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random numbers
Allocation concealment (selection bias) Low risk Randomly assigned in a double-blindman-
ner
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded
Ni 2003
Methods Randomised unblinded parallel group trial. Method of randomisation not reported
Inpatient setting
Participants N = 141 (Group 1: 55; Group 2: 48; Group 3: 38)
No withdrawals occurred and all participants were accounted for
75 M/66 F
Age range: 1 to 12 years
• Inclusion criteria: age between 1 and 12 years admitted with acute asthma
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Ni 2003 (Continued)
• Exclusion criteria: not available
Interventions All treatments were administered via a nebuliser
• Group 1: salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) + ipratropium
bromide (0.25 to1 mL i.e. 62.5 to 250 mcg) diluted to 2 mL with normal saline
• Group 2: 0.5% salbutamol (0.25 to 1 mL i.e. 1250 to 5000 mcg) diluted to 2 mL
with normal saline
• Group 3: 0.025% ipratropium bromide (0.25 to 1 mL i.e. 62.5 to 250 mcg)
diluted to 2 mL with normal saline
Nebulised medications were administered 2 to 4 times a day
Outcomes No symptoms or improved symptoms (shortness of breath, wheeze and hypoxia)
Notes Translated paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
High risk Not double-blinded
Van Bever 1994
Methods Randomised double-blind parallel group trial. Method of randomisation: computerised
random function choosing 10 numbers from 1 to 20, subsequently open study design
Setting not reported
Participants All treatments were administered via blinded metered dose inhalers with aeroscopic
N = 20; 15 M/5 F
Mean age: 12.7 years (age range: 4.9 to 15.1 years)
• Inclusion criteria: children with asthma with mild bronchoconstriction and FEV1
between 50% and 85%; able to perform lung function tests and use a MDI with spacer
appropriately; discontinued bronchodilators > 12 hours prior to study entry
• Exclusion criteria: not available
Interventions • Group 1: oxitropium bromide 200 mcg
• Group 2: fenoterol 200 mcg
Subsequently all patient received 400 mcg fenoterol in an open label study
Outcomes Lung function: FEV1; VC; MEF50; MEF25; medication side effects
21Anticholinergic therapy for acute asthma in children (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Van Bever 1994 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random numbers
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinded metered dose inhalers
Watson 1988
Methods Randomised double-blind parallel group trial. Method of randomisation not reported
Setting not reported
Participants N = 47 (Group 1: 16; Group 2: 15; Group 3: 16)
Age range: 6 to 17 years
• Inclusion criteria: exacerbation of acute asthma, able to perform forced expiratory
manoeuvre, FEV1 30% to 70% predicted
• Exclusion criteria: mild asthma or very severe acute asthma attack with actual or
impending respiratory failure, known hypersensitivity to sympathomimetic or atropinic
compounds, if patient had disorders other than asthma, allergic rhinitis, atopic
dermatitis or prior use of an inhaled bronchodilator within 5 hours of study entry
Interventions • Group 1: ipratropium bromide 250 mcg + fenoterol hydrobromide 625 mcg
diluted to 4 mL isotonic solution
• Group 2: fenoterol 625 mcg diluted to 4 mL isotonic solution
• Group 3: ipratropium bromide 250 mcg diluted to 4 mL isotonic solution
All treatments were administered via a Hudson nebuliser driven by 7 L/min of room air.
Two doses of inhalations were given 60 minutes apart
Outcomes Clinical scores at 30, 60, 90 and 120 min
Oxygen saturation at 30, 60, 90 and 120 min
Spirometry at 30, 60, 90 and 120 min and after nebulised salbutamol
Medication side effects
Notes No mention of the method of randomisation
At end of study, albuterol 0.5% (5000 mcg/mL) (i.e. 0.02 mL/kg (100 mcg/kg)), max
1 mL (5000 mcg), diluted to 2 mL with normal saline) was administered in an open
fashion to assess for possible additional bronchodilatation
Risk of bias
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Watson 1988 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
F: female; FEV1: forced expiratory volume in the first second; IV: intravenous; M: male; mcg: micrograms; MEF50: maximal expiratory
flow at 50% of vital flow capacity; MEF25: maximal expiratory flow at 25% of vital flow capacity; MDI: metered dose inhaler; PEF:
peak expiratory flow; TAL: a clinical scoring system based on several markers such as respiratory rate, wheezing and cyanosis (the
scale runs from 0 to 12, where 12 indicates a very severe illness); VC: vital capacity.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beck 1985 RCT: Beta2-agonist compared with combination anticholinergic and beta2-agonist therapy
BenitoFernandez 2000 RCT: Beta2-agonist compared with combination anticholinergic and beta2-agonist therapy
Bratteby 1986 Non-RCT and chronic asthma. Beta2-agonist compared with combination anticholinergic and beta2-ago-
nist therapy
Browne 2002 Control group did not fulfil criteria. RCT: Beta2-agonist compared with combination anticholinergic and
beta-agonist therapy
Craven 2001 Control group did not fulfil criteria. RCT: Beta2-agonist compared with combination anticholinergic and
beta-agonist therapy
De Stefano 1990 Chronic asthma. Beta2-agonist compared with combination anticholinergic and beta2-agonist therapy
Ducharme 1998 Control group did not fulfil criteria. RCT: Beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Ferres 1988 Children were aged less than 1 year
Goggin 2001 Control group did not fulfil criteria. RCT: Beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
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(Continued)
Hayday 2002 Control group did not fulfil criteria. RCT: Beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Iramain 2011 Control group did not fulfil criteria. RCT:- Beta2-agonist compared with combination anticholinergic and
beta2−agonist therapy
Lew 1990 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta-agonist therapy
Lin 1978 RCT: Combination therapy in non-acute asthma
Mallol 1987 RCT: Infants with acute wheezing
Mirsadraee 2009 RCT: Adult study
Monge 2000 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Pulejo 1986 Control group did not fulfil criteria. Double-blind study: Combination anticholinergic and beta2-agonist
(duovent) therapy compared with placebo
Qureshi 1997 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Qureshi 1998 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Rayner 1987 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Reisman 1988 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Schuh 1995 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Storms 1986 RCT: Chronic asthma
Storr 1986 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Timsit 2002 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
Ulrik 1992 Chronic asthma
Ward 1981 Non-RCT: mainly adult study
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(Continued)
Ward 1985 RCT: mainly adult study
Yeung 1980 Exercise induced asthma
Youngchaiyud 1989 RCT: adult study
Zimmerman 1984 RCT: Chronic asthma
Zorc 1999 Control group did not fulfil criteria. RCT: beta2-agonist compared with combination anticholinergic and
beta2-agonist therapy
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Anticholinergic agents versus short-acting beta2-agonist
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure 4 171 Odds Ratio (M-H, Fixed, 95% CI) 2.27 [1.08, 4.75]
1.1 Ipratropium bromide
versus beta2-agonists
3 143 Odds Ratio (M-H, Fixed, 95% CI) 2.36 [1.02, 5.47]
1.2 Atropine sulphate versus
metaproterenol
1 28 Odds Ratio (M-H, Fixed, 95% CI) 1.97 [0.42, 9.32]
2 Admission to hospital 3 139 Odds Ratio (M-H, Fixed, 95% CI) 5.50 [1.11, 27.16]
2.1 Ipratropium bromide
versus beta2-agonist
2 111 Odds Ratio (M-H, Fixed, 95% CI) 5.34 [0.24, 121.00]
2.2 Atropine sulphate versus
metaproterenol
1 28 Odds Ratio (M-H, Fixed, 95% CI) 5.57 [0.88, 35.27]
3 PEF @ 30 minutes (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Ipratropium bromide
versus salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Atropine sulphate versus
metaproterenol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 PEF @ 120 minutes (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Ipratropium bromide
versus salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FEV1 @ 30 minutes (litres/sec) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Ipratropium bromide
versus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FEV1 @ 30 minutes (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Oxitropium bromide
versus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FEV1 @120 minutes (litres/sec) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Ipratropium bromide
versus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Pulmonary index @ 30 mins 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Ipratropium bromide
versus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Atropine sulfate versus
metaproterenol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Pulmonary index @ 120 mins 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Ipratropium bromide
versus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 2. Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure 4 173 Odds Ratio (M-H, Fixed, 95% CI) 2.65 [1.20, 5.88]
1.1 Ipratropium bromide
versus ipratropium bromide
plus beta2-agonist
3 144 Odds Ratio (M-H, Fixed, 95% CI) 3.67 [1.41, 9.50]
1.2 Atropine sulphate
versus atropine sulphate plus
metaproterenol
1 29 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.21, 4.98]
2 Admission to hospital 3 141 Odds Ratio (M-H, Fixed, 95% CI) 5.90 [1.20, 29.05]
2.1 Ipratropium bromide
versus ipratropium bromide
plus beta2-agonist
2 112 Odds Ratio (M-H, Fixed, 95% CI) 5.69 [0.25, 128.50]
2.2 Atropine sulfate
versus atropine sulfate plus
metaproterenol
1 29 Odds Ratio (M-H, Fixed, 95% CI) 6.0 [0.95, 37.76]
3 Participants requiring no repeat
nebulisation
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Moderate-severe acute
asthma
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 PEF @ 30 minutes (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Ipratropium bromide
versus ipratropium bromide
plus salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Atropine sulphate
versus atropine sulphate plus
metaproterenol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 PEF @ 120 minutes (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Ipratropium bromide
versus ipratropium bromide
plus salbutamol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FEV1 @ 30 minutes (litres/sec) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Ipratropium versus
ipratropium bromide plus
fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 FEV1 @120 mins (litres/sec) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Ipratropium versus
ipratropium bromide plus
fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Pulmonary index @ 30 mins 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Ipratropium bromide
versus ipratropium bromide
plus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Atropine sulfate
versus atropine sulfate plus
metaproterenol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Pulmonary index @ 120 mins 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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9.1 Ipratropium bromide
versus ipratropium bromide
plus fenoterol
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 1
Treatment failure.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 1 Treatment failure
Study or subgroup Anticholinergic Beta2 agonists Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ipratropium bromide versus beta2-agonists
Calvo 1998 11/40 6/40 45.4 % 2.15 [ 0.71, 6.53 ]
Cook 1985 8/16 5/16 26.1 % 2.20 [ 0.52, 9.30 ]
Watson 1988 2/16 0/15 4.6 % 5.34 [ 0.24, 121.00 ]
Subtotal (95% CI) 72 71 76.1 % 2.36 [ 1.02, 5.47 ]
Total events: 21 (Anticholinergic), 11 (Beta2 agonists)
Heterogeneity: Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
2 Atropine sulphate versus metaproterenol
Guill 1987 9/13 8/15 23.9 % 1.97 [ 0.42, 9.32 ]
Subtotal (95% CI) 13 15 23.9 % 1.97 [ 0.42, 9.32 ]
Total events: 9 (Anticholinergic), 8 (Beta2 agonists)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 85 86 100.0 % 2.27 [ 1.08, 4.75 ]
Total events: 30 (Anticholinergic), 19 (Beta2 agonists)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.005 0.1 1 10 200
Favours anticholinergic Favours beta2 agonist
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Analysis 1.2. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 2 Admission
to hospital.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 2 Admission to hospital
Study or subgroup Anticholinergic Beta2 agonists Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ipratropium bromide versus beta2-agonist
Calvo 1998 0/40 0/40 0.0 [ 0.0, 0.0 ]
Watson 1988 2/16 0/15 5.34 [ 0.24, 121.00 ]
Subtotal (95% CI) 56 55 5.34 [ 0.24, 121.00 ]
Total events: 2 (Anticholinergic), 0 (Beta2 agonists)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
2 Atropine sulphate versus metaproterenol
Guill 1987 6/13 2/15 5.57 [ 0.88, 35.27 ]
Subtotal (95% CI) 13 15 5.57 [ 0.88, 35.27 ]
Total events: 6 (Anticholinergic), 2 (Beta2 agonists)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 69 70 5.50 [ 1.11, 27.16 ]
Total events: 8 (Anticholinergic), 2 (Beta2 agonists)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.036)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.002 0.1 1 10 500
Favours anticholinergic Favours beta2 agonist
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Analysis 1.3. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 3 PEF @ 30
minutes (% predicted).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 3 PEF @ 30 minutes (% predicted)
Study or subgroup Anitcholinergic Beta2 agonist
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus salbutamol
Calvo 1998 40 78.1 (7.3) 40 80.5 (7) -2.40 [ -5.53, 0.73 ]
2 Atropine sulphate versus metaproterenol
Guill 1987 11 39 (22) 8 51 (14) -12.00 [ -28.22, 4.22 ]
-50 -25 0 25 50
Favours beta2 agonist Favours anticholinergic
Analysis 1.4. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 4 PEF @
120 minutes (% predicted).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 4 PEF @ 120 minutes (% predicted)
Study or subgroup Ipratropium bromide Salbutamol
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus salbutamol
Calvo 1998 40 95.6 (4.3) 40 95.7 (4.3) -0.10 [ -1.98, 1.78 ]
-10 -5 0 5 10
Favours salbutamol Favours ipratropium
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Analysis 1.5. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 5 FEV1 @
30 minutes (litres/sec).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 5 FEV1 @ 30 minutes (litres/sec)
Study or subgroup Anticholinergic Fenoterol
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus fenoterol
Watson 1988 16 1.51 (0.84) 15 1.86 (0.85) -0.35 [ -0.95, 0.25 ]
-50 -25 0 25 50
Favours fenoterol Favours anitcholinergic
Analysis 1.6. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 6 FEV1 @
30 minutes (% predicted).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 6 FEV1 @ 30 minutes (% predicted)
Study or subgroup Anticholinergic Fenoterol
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Oxitropium bromide versus fenoterol
Van Bever 1994 10 82.9 (9.6) 10 83 (10.1) -0.10 [ -8.74, 8.54 ]
-10 -5 0 5 10
Favours fenoterol Favours anitcholinergic
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Analysis 1.7. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 7 FEV1
@120 minutes (litres/sec).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 7 FEV1 @120 minutes (litres/sec)
Study or subgroup Ipratropium bromide Fenoterol
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus fenoterol
Watson 1988 16 1.48 (0.8) 15 1.89 (0.89) -0.41 [ -1.01, 0.19 ]
-1 -0.5 0 0.5 1
Favours fenoterol Favours ipratropium
Analysis 1.8. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 8
Pulmonary index @ 30 mins.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 8 Pulmonary index @ 30 mins
Study or subgroup Anticholinergic Beta2 agonist
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus fenoterol
Watson 1988 16 4.56 (1.32) 15 3.87 (1.24) 0.69 [ -0.21, 1.59 ]
2 Atropine sulfate versus metaproterenol
Guill 1987 13 5.3 (3.3) 15 3.7 (1.7) 1.60 [ -0.39, 3.59 ]
-4 -2 0 2 4
Favours anticholinergic Favours beta2 agonist
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Analysis 1.9. Comparison 1 Anticholinergic agents versus short-acting beta2-agonist, Outcome 9
Pulmonary index @ 120 mins.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 1 Anticholinergic agents versus short-acting beta2-agonist
Outcome: 9 Pulmonary index @ 120 mins
Study or subgroup Ipratropium bromide Fenoterol
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus fenoterol
Watson 1988 16 4.72 (1.64) 15 2.93 (1.54) 1.79 [ 0.67, 2.91 ]
-10 -5 0 5 10
Favours ipratropium Favours fenoterol
Analysis 2.1. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 1 Treatment failure.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 1 Treatment failure
Study or subgroup Anticholinergics Combination Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus beta2-agonist
Calvo 1998 11/40 2/40 18.3 % 7.21 [ 1.48, 35.07 ]
Cook 1985 8/16 6/16 37.9 % 1.67 [ 0.41, 6.82 ]
Watson 1988 2/16 0/16 5.4 % 5.69 [ 0.25, 128.50 ]
Subtotal (95% CI) 72 72 61.6 % 3.67 [ 1.41, 9.50 ]
Total events: 21 (Anticholinergics), 8 (Combination)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Atropine sulphate versus atropine sulphate plus metaproterenol
Guill 1987 9/13 11/16 38.4 % 1.02 [ 0.21, 4.98 ]
0.005 0.1 1 10 200
Favours anticholinergic Favours combination
(Continued . . . )
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(. . . Continued)
Study or subgroup Anticholinergics Combination Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 13 16 38.4 % 1.02 [ 0.21, 4.98 ]
Total events: 9 (Anticholinergics), 11 (Combination)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 85 88 100.0 % 2.65 [ 1.20, 5.88 ]
Total events: 30 (Anticholinergics), 19 (Combination)
Heterogeneity: Chi2 = 3.57, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 1.84, df = 1 (P = 0.18), I2 =46%
0.005 0.1 1 10 200
Favours anticholinergic Favours combination
Analysis 2.2. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 2 Admission to hospital.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 2 Admission to hospital
Study or subgroup Anticholinergic Combination Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus beta2-agonist
Calvo 1998 0/40 0/40 0.0 [ 0.0, 0.0 ]
Watson 1988 2/16 0/16 5.69 [ 0.25, 128.50 ]
Subtotal (95% CI) 56 56 5.69 [ 0.25, 128.50 ]
Total events: 2 (Anticholinergic), 0 (Combination)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
2 Atropine sulfate versus atropine sulfate plus metaproterenol
Guill 1987 6/13 2/16 6.00 [ 0.95, 37.76 ]
Subtotal (95% CI) 13 16 6.00 [ 0.95, 37.76 ]
Total events: 6 (Anticholinergic), 2 (Combination)
Heterogeneity: not applicable
0.005 0.1 1 10 200
Favours anitcholinergic Favours combination
(Continued . . . )
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(. . . Continued)
Study or subgroup Anticholinergic Combination Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.91 (P = 0.056)
Total (95% CI) 69 72 5.90 [ 1.20, 29.05 ]
Total events: 8 (Anticholinergic), 2 (Combination)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.005 0.1 1 10 200
Favours anitcholinergic Favours combination
Analysis 2.3. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 3 Participants requiring no repeat nebulisation.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 3 Participants requiring no repeat nebulisation
Study or subgroup Ipratropium bromide Combination Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate-severe acute asthma
Cook 1985 8/15 10/15 0.57 [ 0.13, 2.50 ]
0.02 0.1 1 10 50
Favours combination Favours ipratropium
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Analysis 2.4. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 4 PEF @ 30 minutes (% predicted).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 4 PEF @ 30 minutes (% predicted)
Study or subgroup Anticholinergic Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus salbutamol
Calvo 1998 40 78.1 (7.3) 40 85.1 (6.7) -7.00 [ -10.07, -3.93 ]
2 Atropine sulphate versus atropine sulphate plus metaproterenol
Guill 1987 11 39 (22) 10 48 (24) -9.00 [ -28.76, 10.76 ]
-100 -50 0 50 100
Favours combination Favours anticholinergic
Analysis 2.5. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 5 PEF @ 120 minutes (% predicted).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 5 PEF @ 120 minutes (% predicted)
Study or subgroup Anitcholinergic Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus salbutamol
Calvo 1998 40 95.6 (4.3) 40 102 (5.3) -6.40 [ -8.52, -4.28 ]
-20 -10 0 10 20
Favours combination Favours anticholinergic
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Analysis 2.6. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 6 FEV1 @ 30 minutes (litres/sec).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 6 FEV1 @ 30 minutes (litres/sec)
Study or subgroup Ipratropium bromide Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium versus ipratropium bromide plus fenoterol
Watson 1988 16 1.51 (0.84) 16 1.94 (0.93) -0.43 [ -1.04, 0.18 ]
-2 -1 0 1 2
Favours combination Favours ipratropium
Analysis 2.7. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 7 FEV1 @120 mins (litres/sec).
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 7 FEV1 @120 mins (litres/sec)
Study or subgroup Ipratropium bromide Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium versus ipratropium bromide plus fenoterol
Watson 1988 16 1.48 (0.8) 16 2.11 (1.05) -0.63 [ -1.28, 0.02 ]
-1 -0.5 0 0.5 1
Favours combination Favours ipratropium
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Analysis 2.8. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 8 Pulmonary index @ 30 mins.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 8 Pulmonary index @ 30 mins
Study or subgroup Anticholinergic Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus fenoterol
Watson 1988 16 4.56 (1.32) 16 3.53 (1.7) 1.03 [ -0.02, 2.08 ]
2 Atropine sulfate versus atropine sulfate plus metaproterenol
Guill 1987 13 5.3 (3.3) 16 4 (2.4) 1.30 [ -0.84, 3.44 ]
-4 -2 0 2 4
Favours anticholinergic Favours combination
Analysis 2.9. Comparison 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists,
Outcome 9 Pulmonary index @ 120 mins.
Review: Anticholinergic therapy for acute asthma in children
Comparison: 2 Anticholinergic agents versus anticholinergics plus short-acting beta2-agonists
Outcome: 9 Pulmonary index @ 120 mins
Study or subgroup Ipratropium bromide Combination
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ipratropium bromide versus ipratropium bromide plus fenoterol
Watson 1988 16 4.72 (1.64) 16 2.56 (1.39) 2.16 [ 1.11, 3.21 ]
-4 -2 0 2 4
Favours ipratropium Favours combination
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A D D I T I O N A L T A B L E S
Table 1. Outcomes reported
Outcome Calvo Cook Guill Watson Van Bever
Treatment failure Yes: three criteria
(TAL score < 2;
PEF < 15% baseline
measurement; intol-
erance to treatment)
Yes: one criterion
(IV therapy)
Yes: three criteria
for treatment fail-
ure (return visit to
ED within 12 to
24 hours; IV treat-
ment; admission to
hospital)
Yes: one criterion
(admission to hospi-
tal)
No
Admission Yes (No patients re-
quired admission)
No Yes Yes No
PEF Yes (response
to treatment deter-
mined by change in
PEF)
No Yes No No
FEV1 No No No Yes Yes
FEF25−75 No No No Yes No
Residual bron-
chodilation (FEV1
and FEF25−75)
No No No Yes No
Clinical scores Yes (TAL score) Yes (in-house 4-
point scale.Wheeze,
air entry on auscul-
tation, respiratory
distress measured)
Yes (Pulmonary In-
dex - respira-
tory rate, wheezing
score, I/E ratio, ac-
cessory muscle use)
Yes (Pulmonary In-
dex - respira-
tory rate, wheezing
score, I/E ratio, ac-
cessory muscle use)
No
Need for additional
medication
Yes (need for bron-
chodilator/steroid
and repeat nebulisa-
tion)
Yes (repeat nebulisa-
tion and need for IV
therapy)
Yes (repeat nebulisa-
tion and need for IV
therapy)
No No
Withdrawals No patients with-
drew
3 patients had treat-
ment failure and
dropped out
10 episodes of
wheezing had treat-
ment failure
No patients with-
drew; 2 children re-
quired hospital ad-
mission at the end of
the study because of
treatment failure
Not reported
Pulse oximetry No No No Yes No
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Table 1. Outcomes reported (Continued)
Side effects Yes (no patient suf-
fered SEs)
Yes (no patient suf-
fered SEs)
Yes (no patient suf-
fered SEs)
Yes (no patient suf-
fered SEs)
Yes (no patient suf-
fered SEs)
ED: emergency department; FEF25−75 : forced expiratory flow at the 25 to the 75% point of forced vital capacity; FEV1: forced
expiratory volume in the first second; I/E ratio: inspiration/expiration ratio; IV: intravenous; PEF: peak expiratory flow; SE: side
effects; TAL: a clinical scoring system based on several markers such as respiratory rate, wheezing and cyanosis (the scale runs from
0 to 12, where 12 indicates a very severe illness).
Table 2. TAL scores measured in Calvo 1998
Treatment group 0 minutes 15 minutes 30 minutes
Ipratropium (IP) 5.6 (SD 0.7) 5.4 (SD 0.7) 4.2 (SD 0.9)
Salbutamol (SAL) 5.6 (SD 0.7) 4.5 (SD 1.0) 3.3 (SD 1.1)
Combination (IP + SAL) 6.0 (SD 0.8) 4.3 (SD 1.2) 2.8 (SD 1.0)
P value IP versus SAL > 0.05 < 0.01 < 0.01
P value IP versus IP + SAL > 0.05 < 0.01 < 0.01
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
CENTRAL (The Cochrane Library) Quarterly
PsycINFO (Ovid) Monthly
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(Continued)
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
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14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Asthma explode all trees
#2 (asthma*)
#3 (wheez*)
#4 MeSH descriptor Respiratory Sounds, this term only
#5 MeSH descriptor Bronchial Spasm, this term only
#6 (bronchospas*)
#7 (bronch* near/3 spasm*)
#8 (bronchoconstrict*)
#9 MeSH descriptor Bronchoconstriction, this term only
#10 (bronch* near/3 constrict*)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Cholinergic Antagonists explode all trees
#13 anticholinergic* or anti-cholinergic* or cholinergic* or muscarinic* or antimuscarinic or ipratropium or tiotropium or atropine
or atrovent or oxitropium or Sch1000 or duovent
#14 (#12 OR #13)
#15 (#11 AND #14)
#16 MeSH descriptor Child explode all trees
#17 MeSH descriptor Infant explode all trees
#18 MeSH descriptor Adolescent explode all trees
#19 MeSH descriptor Pediatrics explode all trees
#20 child* or paediat* or pediat* or infan* or toddler* or bab* or young* or preschool* or “pre school*” or pre-school* or newborn*
or “newborn*” or new-born* or neo-nat* or neonat*
#21 (#16 OR #17 OR #18 OR #19 OR #20)
#22 (#15 AND #21)
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H I S T O R Y
Protocol first published: Issue 2, 2002
Review first published: Issue 4, 2012
C O N T R I B U T I O N S O F A U T H O R S
The original protocol was written by Satish Bangalore, Anna Bara andNicolaMcDonald. The protocol was revised prior to commencing
the review by Laurel Teoh (LT) and Anne Chang (AC).
LT and AC wrote the review and independently selected, reviewed, and extracted the data from the papers. All authors reviewed the
submitted review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Australian Cochrane Airway Scholarship, Australia.
Support to LT
• National Health and Medical Research Council (NHMRC), Australia.
Fellowship for AC (grant number 545216)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We subgrouped the data by anticholinergic type. We added withdrawals and requirement for additional medication as secondary
outcomes and pooled the data. We removed parent and patient perceptions and physician assessment as outcomes as they are not clearly
defined outcomes.
N O T E S
None relevant.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [∗administration & dosage]; Albuterol [administra-
tion & dosage]; Asthma [∗drug therapy]; Atropine [administration & dosage]; Bronchodilator Agents [∗administration & dosage];
Cholinergic Antagonists [∗administration & dosage]; Drug Therapy, Combination [methods]; Fenoterol [administration & dosage];
Ipratropium [administration & dosage]; Metaproterenol [administration & dosage]; Randomized Controlled Trials as Topic; Scopo-
lamine Derivatives [administration & dosage]; Treatment Failure
MeSH check words
Adolescent; Child; Child, Preschool; Humans
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